CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $313,000 | +7.6% | 4,792 | 0.0% | 0.00% | – |
| Q2 2022 | $291,000 | +22.3% | 4,792 | 0.0% | 0.00% | – |
| Q1 2022 | $238,000 | -34.4% | 4,792 | 0.0% | 0.00% | – |
| Q4 2021 | $363,000 | -83.3% | 4,792 | -75.4% | 0.00% | -100.0% |
| Q3 2021 | $2,178,000 | -39.9% | 19,463 | -13.0% | 0.00% | -33.3% |
| Q2 2021 | $3,623,000 | +0.7% | 22,382 | -24.2% | 0.00% | -25.0% |
| Q1 2021 | $3,599,000 | -37.5% | 29,534 | -21.5% | 0.00% | -33.3% |
| Q4 2020 | $5,760,000 | +112.9% | 37,622 | +16.3% | 0.01% | +100.0% |
| Q3 2020 | $2,706,000 | +292.2% | 32,349 | +244.6% | 0.00% | +200.0% |
| Q2 2020 | $690,000 | -13.3% | 9,388 | -50.0% | 0.00% | 0.0% |
| Q1 2020 | $796,000 | +37.5% | 18,776 | +97.6% | 0.00% | 0.0% |
| Q4 2019 | $579,000 | +48.8% | 9,500 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $389,000 | -63.8% | 9,500 | -74.7% | 0.00% | -66.7% |
| Q4 2018 | $1,075,000 | -36.7% | 37,620 | -1.7% | 0.00% | -25.0% |
| Q3 2018 | $1,697,000 | -28.5% | 38,260 | -5.2% | 0.00% | -20.0% |
| Q2 2018 | $2,372,000 | +21.6% | 40,360 | -5.4% | 0.01% | +25.0% |
| Q1 2018 | $1,950,000 | – | 42,670 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |